# Empress Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/empress-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.empresstx.com
- Total disclosed funding: $40M
- Latest round: Series A (Jun 21, 2023)
- Investors on record: 1

## About

Founded in 2020 and based in Massachusetts, US, Empress Therapeutics, Inc. operates as a drug development company that offers small-molecule drugs. The company was founded by its CEO, Jason Park, Noubar Afeya, Sabrina Yang, John Mendlein, and Doug Cole. In June 2023, Empress Therapeutics, Inc. raised USD 50 million in venture funding from Flagship Pioneering.

Empress Therapeutics offers a Chemilogics platform, a biotech platform that uses patient data, DNA, artificial intelligence, small molecule chemistry, and synthetic biology to discover small molecule drugs in the human body. The company collects metagenomic data from patients to identify genes that encode for small-molecule compounds, uses machine learning to predict their potential drug properties, and develops oral medicines for a variety of diseases.

The company plans to use the funds raised in June 2023 to further develop its drug leads.

## Funding rounds

- Series A, Jun 21, 2023, $40M — Flagship Pioneering

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A